News headlines about Moleculin Biotech (NASDAQ:MBRX) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Moleculin Biotech earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.6264264354969 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Separately, ValuEngine raised Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.

Shares of Moleculin Biotech (MBRX) traded down $0.04 during midday trading on Friday, hitting $1.75. The stock had a trading volume of 84,295 shares, compared to its average volume of 298,083. Moleculin Biotech has a 52 week low of $0.71 and a 52 week high of $3.75.

Moleculin Biotech (NASDAQ:MBRX) last issued its earnings results on Tuesday, November 14th. The company reported ($0.14) earnings per share for the quarter.

WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at

About Moleculin Biotech

Moleculin Biotech, Inc is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).

Insider Buying and Selling by Quarter for Moleculin Biotech (NASDAQ:MBRX)

Receive News & Ratings for Moleculin Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.